Skip to main content

Prime Medicine

Prime Medicine Inc is an American clinical-stage biotechnology enterprise headquartered in Cambridge, Massachusetts. The company specializes in the development of next-generation gene editing therapies, anchored by its proprietary 'Prime Editing' technology platform, designed to precisely correct genetic mutations and treat a wide range of inherited diseases. Principal revenue is currently earned through strategic research collaborations, grant funding, and capital financing arrangements as clinical pipelines advance. Prime Medicine is publicly listed on the Nasdaq Stock Market.

2 of the funds FundTelligence covers report a position in Prime Medicine.

Legal name
Prime Medicine Inc
Sector
Health Care
Country
United States
Funds holding it
2
Exposure themes
Gene Editing, Genetic Medicine, Precision Medicine & Genomics

Funds holding Prime Medicine

Loading...